ArticleInfectious diseases and therapy2022

First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults.

Venkateshan S Prativadibhayankaram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.